Looking At Triple Negative Breast Cancer Patient Experience Patterns in Medical Trials

Power Life Sciences Inc.500 enrolled

Overview

Clinical trials can sometimes favor certain demographic groups. Additionally, there is limited research that delves into the factors that influence participation in clinical trials, both positive and negative. The goal is to identify the obstacles and challenges that prevent participation in Triple Negative Breast Cancer clinical trials, as well as the reasons for withdrawal or discontinuation. The insights gained from this study will ultimately benefit those with Triple Negative Breast Cancer who may be invited to participate in clinical research in the years to come.

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

Triple Negative Breast Cancer Breast Cancer

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥ 18 years * Willing and able to comply with scheduled visits, treatment schedule, laboratory tests and other requirements of the study. * Capable of giving signed informed consent, which includes compliance with requirements and restrictions listed in the informed consent form (ICF) and in the protocol Exclusion Criteria: * Pregnant or lactating woman * Any mental or medical condition that prevents the patient from giving informed consent or participating in the trial * Inability to perform regular electronic reporting

Outcomes

Primary Outcomes

Number of triple negative breast cancer patients who decide to enroll in a clinical study

Time frame: 3 months

Rate of triple negative breast cancer patients who remain in a clinical study to completion

Time frame: 12 months